Appropriate FRAX® Intervention Threshold for Pharmacological Treatment of Osteoporosis in Thailand
暂无分享,去创建一个
[1] Suranut Charoensri,et al. An optimal intervention threshold of FRAX in postmenopausal Thai women , 2022, Archives of Osteoporosis.
[2] N. Watts,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[3] J. Kanis,et al. Temporal changes in access to FRAX® in Thailand between 2010 and 2018 , 2019, Archives of Osteoporosis.
[4] Z. Sheng,et al. Comparison of strategies for setting intervention thresholds for Chinese postmenopausal women using the FRAX model , 2019, Endocrine.
[5] Y. Goh,et al. A comprehensive overview on osteoporosis and its risk factors , 2018, Therapeutics and clinical risk management.
[6] C. Cooper,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2018, Osteoporosis International.
[7] C. Cooper,et al. A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.
[8] Yu-Ching Lin,et al. Application of the World Health Organization Fracture Risk Assessment Tool to predict need for dual-energy X-ray absorptiometry scanning in postmenopausal women. , 2015, Taiwanese journal of obstetrics & gynecology.
[9] C. Cooper,et al. FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK , 2015, Osteoporosis International.
[10] A. Mithal,et al. The Asia-Pacific Regional Audit-Epidemiology, Costs, and Burden of Osteoporosis in India 2013: A report of International Osteoporosis Foundation , 2014, Indian journal of endocrinology and metabolism.
[11] C. Cheung,et al. Possible FRAX-based intervention thresholds for a cohort of Chinese postmenopausal women , 2014, Osteoporosis International.
[12] K. Schlauch,et al. Frax prediction without BMD for assessment of osteoporotic fracture risk. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[13] S. Lekamwasam. Sri Lankan FRAX model and country-specific intervention thresholds , 2013, Archives of Osteoporosis.
[14] S. Yeap,et al. The Malaysian Clinical Guidance on the Management of Postmenopausal Osteoporosis, 2012: A Summary , 2013, International journal of rheumatic diseases.
[15] K. Tsai,et al. Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary , 2013, Journal of Bone and Mineral Metabolism.
[16] C. Pongchaiyakul,et al. Value and validation of RCOST and TOPF clinical practice guideline for osteoporosis treatment. , 2012, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[17] H. Johansson,et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™) , 2008, Osteoporosis International.
[18] O. Johnell,et al. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.